Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients

This study has been completed.
Information provided by:
AMAG Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
First received: November 17, 2005
Last updated: January 7, 2015
Last verified: October 2008
The study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients with chronic kidney disease who are not on dialysis.

Condition Intervention Phase
Drug: ferumoxytol or oral iron
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients Not on Dialysis

Resource links provided by NLM:

Further study details as provided by AMAG Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • The mean change in hemoglobin from baseline.

Secondary Outcome Measures:
  • Change in iron indices.

Estimated Enrollment: 304
Study Start Date: May 2004
Study Completion Date: August 2006
Detailed Description:
This study will evaluate the efficacy and safety of intravenous (IV) ferumoxytol as compared to oral iron in the treatment of anemia in non-dialysis dependent CKD patients. Patients are randomized to receive either two doses of 510 mg of ferumoxytol within one week or 200 mg oral elemental iron daily for three weeks.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients ≥ 18 years.
  • Have chronic kidney disease per K/DOQI guidelines.
  • No change in EPO status during study.
  • Baseline hemoglobin of ≤ 11.0 g/dl.

Exclusion Criteria:

  • Women who are pregnant or lactating.
  • Received another investigational drug or device within 30 days.
  • Recent parenteral or oral iron therapy.
  • Patients with active GI bleeding or acute bleeding within 4 weeks.
  • Patients that have other causes of anemia.
  • Major surgery within 30 days or anticipated or planned major surgery during the study.
  • Patients whose EPO status changes while on study.
  • Patients with active infections.
  • Recent blood transfusions.
  • Patients with any known allergies to iron products.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00255424

United States, California
Encino, California, United States, 91356
Riverside, California, United States, 92501
Tarzana, California, United States, 91356
United States, Florida
Ocala, Florida, United States, 34471
United States, Louisiana
Shreveport, Louisiana, United States, 71101
Shreveport, Louisiana, United States, 71103
United States, Massachusetts
Springfield, Massachusetts, United States, 01107
United States, Michigan
Detroit, Michigan, United States, 48236
United States, New York
Flushing, New York, United States, 11355
Orchard Park, New York, United States, 14127
United States, Ohio
Columbus, Ohio, United States, 43210
United States, Pennsylvania
Hershey, Pennsylvania, United States, 17033
Lancaster, Pennsylvania, United States, 17604
United States, Tennessee
Chattanooga, Tennessee, United States, 37404
Knoxville, Tennessee, United States, 37923
United States, Texas
Houston, Texas, United States, 77074
United States, Virginia
Fairfax, Virginia, United States, 22030
United States, West Virginia
Bluefield, West Virginia, United States, 24701
United States, Wisconsin
Appleton, Wisconsin, United States, 54911
Sponsors and Collaborators
AMAG Pharmaceuticals, Inc.
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00255424     History of Changes
Other Study ID Numbers: 62745-6 
Study First Received: November 17, 2005
Last Updated: January 7, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Urologic Diseases
Ferrosoferric Oxide
Parenteral Nutrition Solutions
Pharmaceutical Solutions

ClinicalTrials.gov processed this record on May 24, 2016